Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
[Abstract]2024 Oct 25:140:112844
Participants with prediabetes at baseline dropped from 50.7% to 20.3% at the end of the trial
Archived from the original on 3 August 2023
Preliminary results from the SURPASS-J-mono study in Japanese patients with T2D who were either therapy nave or on an antidiabetic monotherapy showed a head-to-head comparison of a tirzepatide treatment compared to therapy with the GLP-1RA dulaglutide at a dose of 0.75 mg (76)
US$ 20.59
US$ 28.48
US$ 20.86
US$ 20.63
US$ 23.69
